BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology
company specializing in targeted immunotherapies for advanced
breast cancer, is pleased to announce that the data of its clinical
studies with its lead product candidate, Bria-IMT™, will be
presented the at the Annual Symposium of Society of Surgical
Oncology (SSO) 2020 – International Conference on Surgical Cancer
Care taking place March 25-28 in Boston, MA.
The poster will summarize data of the Bria-IMT™
Phase I/IIa clinical studies of Bria-IMT™ in combination with
immune checkpoint inhibitors including pembrolizumab (KEYTRUDA®;
manufactured by Merck & Co., Inc.), and more recently, Incyte’s
INCMGA00012, in advanced breast cancer. The trials are being
conducted by Cancer Insight as the CRO at multiple sites across the
U.S.
Details of the poster presentations are the
following:
Title: Results of a Phase I/IIa
Trial of Combination Whole-Cell Targeted Immunotherapy Vaccine and
Checkpoint Inhibitor in Treatment of Metastatic/Recurrent Breast
CancerAbstract ID: 3288355Final
ID: P40Presenter: Dr. Phillip Kemp
BohanSession: ePosters: Immuno-Oncology in Breast
CancerSession Date: March 26, 2020Session
Time: 10:30 – 11:00 a.m. ETRoom:
Immuno-Oncology Zone Theater (Hynes Convention Center)
Copies of the posters will be posted at the
following:
https://briacell.com/novel-technology/scientific-publications/.
"We continue to be enthusiastic about our data
which indicates additive or synergistic activity of Bria-IMT™ and
checkpoint inhibitors in women who have failed a number of prior
treatments," said Dr. Bill Williams, President & CEO of
BriaCell. "In particular, we will be discussing a subset of
patients that appears to derive tremendous clinical benefit from
the combination therapy. While the dose escalation part of the
ongoing collaborative study with Incyte is focused on evaluating
the safety of the combination, we already see evidence of clinical
activity, particularly with Bria-IMT™ in combination with
INCMGA00012. We look forward to learning more about the efficacy
profile of this novel combination as we continue to treat breast
cancer patients with limited therapeutic options and a grim
prognosis."
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
About Cancer Insight
Founded in 2014, Cancer Insight, LLC, is a
Texas-based clinical research organization (CRO) dedicated to
discovering, developing and testing emerging biotechnologies
specializing in cancer immunotherapy. Cancer Insight offers a
vertical range of CRO services from trial design to final
execution, with a foundation grounded on decades of academic
research and clinical trial experience.
For additional information on Cancer Insight, please visit:
https://www.cancerinsight.com.
About SSO 2020 Annual
Symposium
Over the years, the SSO 2020 annual symposium
has become a meeting venue for practitioners around the world to
discuss and offer expertise on a range of cancer related topics.
The 2020 symposium sessions are comprehensive in the range of
topics and the depth of expertise delivered. Management of Breast
Cancer in Women Age 70+ will be a focused symposium section.
SSO 2020 will feature the debut of SSO HUB, a
new and interactive experience that replaces the conventional
exhibit hall. The HUB will feature five clinical zones –
Breast/Endocrine, HPB, Melanoma/Sarcoma, Colorectal/Upper GI and
Immuno-Oncology. Each Zone will have a theater where posters,
videos and meet the expert sessions will take place. All of this in
addition to the HUB main stage where one may view debates,
challenging case reviews, industry spotlights, clinical trial
spotlights and team competitions.
For Additional information on the SSO 2020,
please
visit: https://www.surgonc.org/events/international-conference-on-surgical-cancer-care/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024